Associated Genetic Biomarkers
NCI Definition: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma. 
Astrocytomas most frequently harbor alterations in TP53, IDH1, ATRX, EGFR, and CDKN2A .
TP53 Mutation, IDH1 Mutation, IDH1 Codon 132 Missense, TP53 Missense, and TP53 c.217-c.1178 Missense are the most common alterations in astrocytoma .
There are 15 clinical trials for astrocytoma, of which 13 are open and 2 are completed or closed. Of the trials that contain astrocytoma as an inclusion criterion, 1 is early phase 1 (1 open), 3 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (6 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open).
IDH1, IDH2, and ATRX are the most frequent gene inclusion criteria for astrocytoma clinical trials .
Temozolomide, ag-881, and bevacizumab are the most common interventions in astrocytoma clinical trials.
Significant Genes in Astrocytoma
IDH1 is altered in 38.44% of astrocytoma patients .
IDH1 is an inclusion eligibility criterion in 4 clinical trials for astrocytoma, of which 4 are open and 0 are closed. Of the trials that contain IDH1 status and astrocytoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) .
IDH2 is altered in 1.09% of astrocytoma patients .
IDH2 is an inclusion eligibility criterion in 3 clinical trials for astrocytoma, of which 3 are open and 0 are closed. Of the trials that contain IDH2 status and astrocytoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.